Abbott Receives FDA Clearance For Assert-IQ Insertable Cardiac Monitor
Portfolio Pulse from Benzinga Newsdesk
Abbott has received FDA clearance for its Assert-IQ Insertable Cardiac Monitor, a device designed to help physicians remotely monitor patients with irregular heart rhythms.
May 18, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Abbott's FDA clearance for Assert-IQ Insertable Cardiac Monitor may boost its market position in the cardiac monitoring space.
Abbott's Assert-IQ Insertable Cardiac Monitor has received FDA clearance, which is a significant regulatory milestone. This approval will allow the company to market and sell the device in the US, potentially increasing its market share in the cardiac monitoring space. The news is highly relevant and important for investors, as it may positively impact Abbott's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100